Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NewGenIvf GroupNIVF -9.09%14 EBITDA Margin % is -510.46% as of Dec. 2025. GuruFocus rates NIVF with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 663 Healthcare Providers & Services companies, NewGenIvf Group ranks better than 99.55% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. NewGenIvf Group's EBITDA for the
three
months ended in Dec. 2025 was $-7.27 Mil. NewGenIvf Group's Revenue for the
three
months ended in Dec. 2025 was $1.43 Mil. Therefore, NewGenIvf Group's EBITDA margin for the quarter that ended in Dec. 2025 was -510.46%.
NewGenIvf Group (NAS:NIVF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
NewGenIvf Group EBITDA Margin % Related Terms
NewGenIvf Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for NewGenIvf Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NIVF vs RHEP, XCRT, SYRA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, NewGenIvf Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NewGenIvf Group EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, NewGenIvf Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where NewGenIvf Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NewGenIvf Group (NIVF) has a EBITDA Margin % of -510.46% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on NewGenIvf Group and its competitors. Over the past decade, NewGenIvf Group's EBITDA Margin % has ranged from 0.44 to 351.76. According to the industry distribution chart, NewGenIvf Group ranks #3 out of 663 companies in the Healthcare Providers & Services industry, placing it in the top 0.5%.
Is NewGenIvf Group's EBITDA Margin % too high?
NewGenIvf Group's current EBITDA Margin % is -510.46%. Over the past 10 years, this metric has ranged from a low of 0.44 to a high of 351.76. Based on the distribution chart, NewGenIvf Group ranks #3 out of 663 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, NewGenIvf Group has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does NewGenIvf Group's EBITDA Margin % compare to RHEP and XCRT?
According to the Healthcare Providers & Services industry distribution chart, NewGenIvf Group ranks #3 out of 663 companies for EBITDA Margin %. This places NewGenIvf Group in the top 1% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.23. Historically, NewGenIvf Group's own EBITDA Margin % has ranged from 0.44 to 351.76 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.23, based on 663 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on NewGenIvf Group and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NewGenIvf Group's current EBITDA Margin % is -510.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewGenIvf Group stock overvalued right now?
NewGenIvf Group (NIVF) has a current EBITDA Margin % of -510.46%. The current EBITDA Margin % is -510.46%. NewGenIvf Group's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For NewGenIvf Group (NIVF), the current EBITDA Margin % is -510.46% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NewGenIvf Group Ltd is a tech-forward, diversified, multi-jurisdictional entity capitalizing on emerging opportunities across real estate development, digital asset innovation, and reproductive health solutions. The company offers two services, namely: in vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and fertility referral services, like surrogacy and ancillary caring services. It derives maximum revenue from in vitro fertilization (IVF) treatment service. Its Geographical presence is in China / HK SAR, Thailand, Cambodia, U.S and Kyrgyzstan. The company derives maximum revenue from Kyrgyzstan.
14GF Score
Get the complete analysis for NIVF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NIVF has been successfully added to your 
